Skip to main content
OpenTrials
Completed

NCT Number: NCT02324647

Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield

Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the presence of hormonal hypersecretion or adrenocortical carcinoma (ACC), respectively. The overall aim of this study is to improve the cost-effectiveness of the diagnostic strategy for AI. Cost-effectiveness of urine steroid profiling (USP) will be compared to the standard diagnostic strategy of repeated CT-imaging.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Medical Center Groningen

Groningen, Provincie Groningen, 9700 RB, Netherlands

About this study

Rationale: Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the presence of hormonal hypersecretion or adrenocortical carcinoma (ACC),respectively. With respect to the diagnosis of ACC, the health benefits of this strategy are controversial for the following reasons: a. critical appraisal of literature has revealed a much lower ACC frequency of 1.9% than previously presumed; b. CT sensitivity and specificity are suboptimal; c. risk of unnecessary adrenalectomies; d. exposure to ionising radiation; e. risk of CT contrast reactions (nephropathy, allergic reaction); f. health care related and economical costs. The hypothesis to be tested is that incorporation of a single baseline urinary steroid profiling (USP) into the management algorithm of AI is more cost-effective than a strategy solely based on repeat CT-scanning.

Objective: SERENDIPITY aims to improve the cost-effectiveness of the diagnostic strategy for AI by the application of a single baseline USP. In addition, we aim to examine the psychological impact for patients with AI being currently subjected to repeated laboratory tests and CT-scanning during several years.

Study design: This is a prospective observational multicenter study. Study population: Patients are eligible if they meet the following inclusion criteria: adrenal mass > 1 cm in diameter incidentally discovered during CT or MRI-scanning, performed for reasons other than an evaluation for adrenal disease and age 18 years or older. The exclusion criteria are: extra-adrenal malignancy (i.e. active or past medical history of malignancy, except for basal cell carcinoma), radiologic diagnosis of simple cyst or bilateral adrenal masses, allergy to radiocontrast, renal insufficiency (i.e. eGFR < 30 ml/min/1.73m2), pregnancy or inability to understand written Dutch.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • discrete adrenal mass > 1 cm in diameter incidentally discovered during CT/MRI-scanning, performed for reasons other than an evaluation for adrenal disease
  • detection CT/MRI-scan performed ≤ 4 months ago
  • age 18 years or older.

Exclusion criteria

  • extra-adrenal malignancy (i.e. active or past medical history of malignancy, except for basal cell carcinoma)
  • radiologic diagnosis of simple cyst or bilateral adrenal masses
  • allergy to radiocontrast
  • renal insufficiency (i.e. eGFR < 30 ml/min/1.73m2)
  • pregnancy
  • adrenal incidentaloma visible on previous (i.e. > 4 months ago) CT/MRI-scan
  • inability to understand written Dutch.

Treatment and study plan

Primary outcomes

  1. Cost-effectiveness

    Time frame: 2 years

    difference in cost-effectiveness of the current management strategy based on repeat CT-scanning to detect ACC among patients with an AI compared with a strategy using a single baseline USP

Secondary outcomes

  1. frequency of ACC among patients with AI at baseline or during follow-up

    Time frame: 2 years

  2. determination of the percentage of AI that meets the criteria of a malignant CT- phenotype at baseline or during follow-up

    Time frame: 2 years

  3. distribution of pathologic diagnosis in surgically removed adrenal glands

    Time frame: 2 years

  4. QoL in patients with an AI at baseline and during follow-up

    Time frame: 2 years

  5. frequency distribution between hormonal hypersecreting and non-functional AI

    Time frame: 2 years

  6. conversion rate from non-functioning AI towards a hypersecreting AI during follow-up

    Time frame: 2 years

  7. costs of diagnostic procedures and surgical interventions

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Amsterdam UMC, location VUmc
  • Canisius-Wilhelmina Hospital
  • Diakonessenhuis, Utrecht
  • Elisabeth-TweeSteden Ziekenhuis
  • Erasmus Medical Center
  • Flevoziekenhuis
  • Frisius Medisch Centrum
  • Haga Hospital
  • Isala
  • Kennemer Gasthuis
  • Leiden University Medical Center
  • Maastricht University Medical Center
  • Martini Hospital Groningen
  • Maxima Medical Center
  • Meander Medical Center
  • Medical Center Alkmaar
  • Medisch Spectrum Twente
  • Onze Lieve Vrouwe Gasthuis
  • Radboud University Medical Center
  • Rijnstate Hospital
  • St. Antonius Hospital
  • Tergooi Hospital
  • Treant ziekenhuis
  • UMC Utrecht
  • Vlietland Ziekenhuis

Registry information

Acronym: SERENDIPITY

Important dates

Study start
2015
Primary completion
2023
Study completion
2023
First posted
Dec 24, 2014
Registry last updated
Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.